血小板生成调节和人工制备的研究进展

doi:10.3969/j.issn.1004-616x.2021.03.014

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (3): 236-240.doi: 10.3969/j.issn.1004-616x.2021.03.014

血小板生成调节和人工制备的研究进展

张竞予^1,2, 张雨杭^1,2, 于兵¹, 陈费¹, 朱海英¹, 胡以平¹, 汪超¹

1. 海军军医大学基础医学院细胞生物学教研室, 上海 200433;
2. 海军军医大学基础医学院学员一大队, 上海 200433

收稿日期:2020-11-17 修回日期:2021-03-01 出版日期:2021-05-30 发布日期:2021-06-09
通讯作者: 胡以平，E-mail：yphu@smmu.edu.cn;汪超，E-mail：wangchaosmmu@126.com E-mail:yphu@smmu.edu.cn;wangchaosmmu@126.com
作者简介:张竞予，E-mail：kaciwhale@foxmail.com。
基金资助:
国家重大科学研究计划（2018YFA0107500）；海军军医大学本科学员创新实践能力孵化基地项目（FH2019011）

Received:2020-11-17 Revised:2021-03-01 Online:2021-05-30 Published:2021-06-09

摘要/Abstract

摘要： 血小板输注对于血小板减少的出血性疾病的治疗意义重大，然而用于输注的血小板产品受到保质期短、易被污染、捐献者少、存在不同程度免疫反应等多方面因素限制，无法实现稳定供应。尤其是在严重自然灾害、战时等突发情况下，血小板储备量极其有限、新鲜制备条件不足，往往无法充分发挥血小板的效能。因此研发新型人工血小板以及改良血小板生产、输注技术具有重大的民用及军用价值。本文综述了与人工血小板技术相关的血小板生成与调节机制，及相关生物技术与生物反应器的发展，以期为后继研究提供参考。

关键词: 血小板, 人工血小板, 干细胞, 生物工程, 再生医学

中图分类号:

R331.1+43

张竞予, 张雨杭, 于兵, 陈费, 朱海英, 胡以平, 汪超. 血小板生成调节和人工制备的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 236-240.

参考文献

[1] NAGELKERKE S Q, PORCELIJN L, GEISSLER J, et al. The association and functional relevance of genetic variation in low-tomedium-affinity Fc-gamma receptors with clinical platelet transfusion refractoriness[J]. J Thromb Haemost, 2020, 18(8): 2047-2053.
[2] STEFELY J A, GAILEY M, KNUDSON M, et al. Retrospective cohort studies of repeat donors reveal donor-dependent variability in the recovery of transfused platelets[J]. Transfusion, 2020, 60(8): 1837-1845.
[3] NURHAYATI R W, OJIMA Y, TAYA M. Recent developments in ex vivo platelet production[J]. Cytotechnology, 2016, 68(6): 2211-2221.
[4] POTTS K S, SARGEANT T J, MARKHAM J F, et al. A lineage of diploid platelet-forming cells precedes polyploid megakaryocyte formation in the mouse embryo[J]. Blood, 2014, 124(17): 2725-2729.
[5] LEFRANÇAIS E, ORTIZ-MUÑOZ G, CAUDRILLIER A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]. Nature, 2017, 544(7648): 105-109.
[6] LOONEY M R. The incomparable platelet: holy alveoli![J]. Blood, 2018, 132(11): 1088-1089.
[7] LOONEY M R, HEADLEY M B. Live imaging of the pulmonary immune environment[J]. Cell Immunol, 2020, 350: 103862.
[8] ALVARADO L J, HUNTSMAN H D, CHENG H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-Γ[J]. Blood, 2019, 133(19): 2043-2055.
[9] ETO K. Platelets using iPS cell technology； large scale manufacturing [J]. J Stem Cells Regen Med, 2019, 15(2): 52.
[10] HANSEN M, VON LINDERN M, VAN DEN AKKER E, et al. Humaninduced pluripotent stem cell-derived blood products: state of the art and future directions[J]. FEBS Lett, 2019, 593(23): 3288-3303.
[11] TAKAYAMA N, NISHIMURA S, NAKAMURA S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells[J]. J Exp Med, 2010, 207(13): 2817-2830.
[12] NAKAMURA S, TAKAYAMA N, HIRATA S, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells[J]. Cell Stem Cell, 2014, 14(4): 535-548.
[13] SHEPHERD J H, HOWARD D, WALLER A K, et al. Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity[J]. Biomaterials, 2018, 182: 135-144.
[14] BLUTEAU O, LANGLOIS T, RIVERA-MUNOZ P, et al. Developmental changes in human megakaryopoiesis[J]. J Thromb Haemost, 2013, 11(9): 1730-1741.
[15] POTTS K S, SARGEANT T J, MARKHAM J F, et al. A lineage of diploid platelet-forming cells precedes polyploid megakaryocyte formation in the mouse embryo[J]. Blood, 2014, 124(17): 2725-2729.
[16] MATSUBARA Y, SAITO E, SUZUKI H, et al. Generation of megakaryocytes and platelets from human subcutaneous adipose tissues [J]. Biochem Biophys Res Commun, 2009, 378(4): 716-720.
[17] MATSUBARA Y, SUZUKI H, IKEDA Y, et al. Generation of megakaryocytes and platelets from preadipocyte cell line 3T3-L1, but not the parent cell line 3T3, in vitro[J]. Biochem Biophys Res Commun, 2010, 402(4): 796-800.
[18] ONO-URUGA Y, TOZAWA K, HORIUCHI T, et al. Human adipose tissue-derived stromal cells can differentiate into megakaryocytes and platelets by secreting endogenous thrombopoietin[J]. J Thromb Haemost, 2016, 14(6): 1285-1297.
[19] TOZAWA K, ONO-URUGA Y, YAZAWA M, et al. Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line[J]. Blood, 2019, 133(7): 633-643.
[20] GAUR M, KAMATA T, WANG S, et al. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function[J]. J Thromb Haemost, 2006, 4(2): 436-442.
[21] TAKAYAMA N, NISHIKII H, USUI J, et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGFpromoted structures that concentrate hematopoietic progenitors[J]. Blood, 2008, 111(11): 5298-5306.
[22] HUANG N, LOU M, LIU H, et al. Identification of a potent small molecule capable of regulating polyploidization, megakaryocyte maturation, and platelet production[J]. J Hematol Oncol, 2016, 9(1): 136.
[23] JAROCHA D, VO K K, LYDE R B, et al. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors[J]. Blood Adv, 2018, 2(6): 597-606.
[24] SIX K R, SICOT G, DEVLOO R, et al. A comparison of haematopoietic stem cells from umbilical cord blood and peripheral blood for platelet production in a microfluidic device[J]. Vox Sang, 2019, 114(4): 330-339.
[25] MARINI I, RIGONI F, ZLAMAL J, et al. Blood donor-derived buffy coat to produce platelets in vitro[J]. Vox Sang, 2020, 115(1): 94-102.
[26] 索伦·斯特芬森, 格拉尔德·贝斯特, 盖伊·赫尔曼斯, 等. 结合聚集蛋白聚糖的免疫球蛋白: CN110997716A[P]. 2020-04-10.
[27] 卡伦·西莱恩克. 治疗性多肽, 其同源物、其片段及其在调节血小板介导的聚集方面的应用: CN101412759[P]. 2009-04-22.
[28] 卢信彤, 关秀茹. 血小板及其替代物输注的研究进展[J]. 医学综述, 2017, 23(15): 3012-3016.
[29] SANTO V E, GOMES M E, MANO J F, et al. Chitosan-chondroitin sulphate nanoparticles for controlled delivery of platelet lysates in bone regenerative medicine[J]. J Tissue Eng Regen Med, 2012, 6(Suppl 3): s47-s59.
[30] LI Y, KNISS D A, LASKY L C, et al. Culturing and differentiation of murine embryonic stem cells in a three-dimensional fibrous matrix[J]. Cytotechnology, 2003, 41(1): 23-35.
[31] SULLENBARGER B, BAHNG J H, GRUNER R, et al. Prolonged continuous in vitro human platelet production using three-dimensional scaffolds[J]. Exp Hematol, 2009, 37(1): 101-110.
[32] DI BUDUO C A, WRAY L S, TOZZI L, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies[J]. Blood, 2015, 125(14): 2254-2264.
[33] BLIN A, LE GOFF A, MAGNIEZ A, et al. Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics[J]. Sci Rep, 2016, 6: 21700.
[34] ITO Y, NAKAMURA S, SUGIMOTO N, et al. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production[J]. Cell, 2018, 174(3): 636-648.
[35] AVANZI M P, OLUWADARA O E, CUSHING M M, et al. A novel bioreactor and culture method drives high yields of platelets from stem cells[J]. Transfusion, 2016, 56(1): 170-178.
[36] BEAU MITCHELL W, AVANZI M P. Megakaryocyte and platelet production from stem cells: US9574178[P]. 2017-02-21.

血小板生成调节和人工制备的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	虞欣璐, 于兵, 王辰, 张红霞, 朱海英. 基于四环素诱导型Hnf1β和Foxa3表达载体的小鼠胚胎成纤维细胞转分化为肝干细胞的实验体系研究[J]. 癌变·畸变·突变, 2021, 33(3): 163-171.
[2]	焦文静, 郭秀娟, 邵俊国, 焦文鹏, 张金艳. 中性粒细胞和血小板与淋巴细胞比值对食管鳞癌临床病理特征及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 213-217.
[3]	于志强, 孙运, 陈小青, 刘汉伟, 马中春. 麻痹性贝类毒素体外生物毒性检测方法的建立[J]. 癌变·畸变·突变, 2019, 31(4): 323-326.
[4]	陈昕涛, 王敏君, 严文韬, 孙宇, 杨桃, 朱海英, 胡以平, 陈费. 1型糖尿病动物模型和干细胞治疗的研究进展[J]. 癌变·畸变·突变, 2019, 31(4): 327-330.
[5]	崔宏伟, 苏秀兰. 胃癌干细胞在胃癌靶向治疗中的研究进展[J]. 癌变·畸变·突变, 2018, 30(6): 490-493.
[6]	刘丹, 焦良波, 张文, 王心怡, 陈涛, 胡卫. QHF复方对人肝癌Huh7细胞生长、侵袭及肿瘤干细胞表面标志物表达的影响[J]. 癌变·畸变·突变, 2018, 30(3): 171-175.
[7]	任雪丹, 李诺, 吕中明, 王民生. 邻苯二甲酸二辛酯亚慢性暴露对SD大鼠血细胞的影响[J]. 癌变·畸变·突变, 2018, 30(2): 140-143,149.
[8]	周明, 孙震晓. 人尿源性干细胞的原代培养[J]. 癌变·畸变·突变, 2017, 29(5): 390-393.
[9]	王龙, 安慧蒙, 彭为, 王亚运, 张勇, 郑鹏飞, 程志斌. 胆管癌干细胞标志的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 402-405.
[10]	杨丽, 张小茜, 张孟贤. Notch信号通路对胶质瘤干细胞作用机制的研究进展[J]. 癌变·畸变·突变, 2017, 29(4): 322-324.
[11]	夏学阳, 郑鑫林, 丁楠, 张建华, 王成, 李斌. 肺癌干细胞培养、鉴定及其应用的研究进展[J]. 癌变·畸变·突变, 2016, 28(4): 321-324.
[12]	郑鑫林, 夏学阳, 张金周, 张建华, 李斌. 食管癌干细胞相关标记物及其分离和鉴定的研究进展[J]. 癌变·畸变·突变, 2016, 28(3): 246-249.
[13]	葛鹏新, 李鹏飞, 杜丽, 韩春光, 原美茹, 李慧, 马艳丽, 刘永学. 奥美拉唑对氯吡格雷抗血栓药效的影响[J]. 癌变·畸变·突变, 2015, 27(6): 477-479.
[14]	野娜, 韩世愈, 王娇. 核干细胞因子在干细胞和肿瘤细胞自我更新中的作用[J]. 癌变·畸变·突变, 2015, 27(5): 404-405,409.
[15]	孔丹, 郝卫东, 蒋建军, 尚兰琴, 魏雪涛, 时褔礼. 利用胚胎干细胞试验模型评价矮壮素的发育毒性[J]. 癌变·畸变·突变, 2015, 27(4): 260-265,271.